#187: Jason: Re: World Bank and Merck & Co., Inc., Announce U.S. $50 Million Funding Initiative to Eliminate River Blindness in Africa
Clinical Manifestations and PathogenesisOnchocerciasis is
better known as river... |
December 8, 2007
07:37:45 AM |
#186: FastFun: World Bank and Merck & Co., Inc., Announce U.S. $50 Million Funding Initiative to Eliminate River Blindness in Africa
The World Bank and Merck & Co., Inc. today announced an initiative... |
December 8, 2007
06:30:03 AM |
#185: FastFun: Merck Anticipates Earnings per Share Growth in 2008; Reaffirms Long-Term, Double-Digit Compound Annual EPS Growth from 2005 to 2010, Excluding Certain Items
Full-Year 2007 Anticipated non-GAAP EPS Range of $3.08 to $3.14,... |
December 8, 2007
06:29:27 AM |
#184: FastFun: Merck's ROTATEQ(R) Reduced Hospitalizations and Emergency Department Visits Due to G9P1A(8) Rotavirus by 100 Percent as Shown by Post-hoc Analysis of Data
The prescribing information for Merck & Co., Inc.'s ROTATEQ®... |
December 8, 2007
06:28:50 AM |
#183: Stock News Bot: MRK News Merck and Schering-Plough to Develop Another New Cholesterol Lowering Medicine
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK)... |
March 26, 2007
05:30:00 AM |
#182: Stock News Bot: MRK News Acumen Pharmaceuticals Inc. Announces Milestone Achievement in Collaboration With Merck & Co., Inc.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Acumen Pharmaceuticals Inc., a... |
January 22, 2007
10:00:00 AM |
#181: Stock News Bot: MRK News Plaintiff Drops VIOXX(R) Suit against Merck Five Weeks Before First Trial in Philadelphia State Court
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Just five weeks before trial was set to... |
January 22, 2007
05:46:00 AM |
#180: Stock News Bot: MRK News VIOXX(R) Plaintiffs Failed to Prove Their Cases
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--A state court judge in Los Angeles... |
January 18, 2007
04:54:00 PM |
#179: Stock News Bot: MRK News Oji Paper Co., Ltd. Licenses the Rosetta Resolver(R) Gene Expression Data Analysis System from Rosetta Biosoftware
SEATTLE & TOKYO--(BUSINESS WIRE)--Rosetta Biosoftware announced today that Oji... |
January 16, 2007
08:00:00 AM |
#178: Stock News Bot: MRK News Merck to Hold Fourth-Quarter 2006 Sales and Earnings Conference Call and Webcast on Jan. 30
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. will hold a... |
January 4, 2007
09:00:00 AM |
#177: Stock News Bot: MRK News Eisai Co., Ltd. Licenses the Elucidator(R) Protein Expression Data Analysis System from Rosetta Biosoftware
SEATTLE & TOKYO--(BUSINESS WIRE)--Rosetta Biosoftware announced today that Eisai... |
January 2, 2007
08:00:00 AM |
#176: Stock News Bot: MRK News Merck & Co., Inc. Announces Completion of Acquisition of Sirna Therapeutics, Inc.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK) today... |
December 29, 2006
09:30:00 AM |
#175: Stock News Bot: MRK News Data Recently Published in Mayo Clinic Proceedings Showed VYTORIN(R) (ezetimibe/simvastatin) Superior to Lipitor (atorvastatin) in Reducing LDL ''Bad'' Cholesterol in Patients with Type II Diabetes at the Dose Comparisons Studied
WHITEHOUSE STATION, N.J. & KENILWORTH, N.J.--(BUSINESS WIRE)--Results from a... |
December 21, 2006
06:00:00 AM |
#174: Stock News Bot: MRK News Merck and Vertex Announce Start of Pivotal Phase 2 Clinical Trial for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680) in Patients with Treatment-Resistant Forms of Advanced Leukemias
WHITEHOUSE STATION, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merck & Co.,... |
December 21, 2006
05:30:00 AM |
#173: Stock News Bot: MRK News REPEAT/FDA Approves New Indication for INVANZ(R) (ertapenem) for the Prevention of Surgical Site Infections (SSI) following Elective Colorectal Surgery in Adults
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. announced today... |
December 21, 2006
05:00:00 AM |
